The comparative efficacy and safety of teicoplanin and vancomycin

Journal of Antimicrobial Chemotherapy

Volumn 37, Issue 2, 1996, Pages 209-222

  Wood, Martin J ^a  

^a BIRMINGHAM HEARTLANDS HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

POLYPEPTIDE ANTIBIOTIC AGENT; TEICOPLANIN; VANCOMYCIN;

BACTERIAL INFECTION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; META ANALYSIS; NEPHROTOXICITY; OTOTOXICITY; RANDOMIZED CONTROLLED TRIAL; REVIEW;

ANTI-BACTERIAL AGENTS; HUMANS; META-ANALYSIS; RANDOMIZED CONTROLLED TRIALS; STATISTICS; TEICOPLANIN; VANCOMYCIN;

EID: 0029947613     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/37.2.209     Document Type: Review

References (27)

1. Al Wali, W., Baillod, R. A., Brumfitt, W. & Hamilton-Miller J. M. T. (1992). Teicoplanin in the treatment of peritonitis during continuous ambulatory peritoneal dialysis: a comparative trial against vancomycin. International Journal of Antimicrobial Agents 1, Suppl. 1, 1-6.
2. Bowley, J. A., Pickering, S. J., Scantlebury, A. J., Ackrill, P. & Jones, D. M. (1988). Intraperitoneal teicoplanin in the treatment of peritonitis associated with continuous ambulatory peritoneal dialysis. Journal of Antimicrobial Chemotherapy 21, Suppl. A, 133-9.
3. Campoli-Richards, D. M., Brogden, R.N. & Faulds, D. (1990). Teicoplanin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential. Drugs 40, 449-86.
4. Charbonneau, P., Harding, I., Garraud, J. J., Aubertin, J., Brunet, F. & Domart, Y. (1994). Teicoplanin : a well-tolerated and easily administered alternative to vancomycin for Gram-positive infections in intensive care patients. Intensive Care Medicine 20, Suppl. 4, S35-42.
5. Chomarat, M., Espinouse, D. & Flandrois, J.-P. (1991). Coagulase-negative staphylococci emerging during teicoplanin therapy and problems in the determination of their sensitivity. Journal of Antimicrobial Chemotherapy 27, 475-80.
6. Cony-Makhoul, P., Brossard, G., Marit, G., Pellergrin, J. L., Texier-Maugein, J. & Reiffers, J. (1990). A prospective study comparing vancomyin and teicoplanin as second-line empiric therapy for infection in neutropenic patients. British Journal of Haematology 76, Suppl. 2, 35-40.
7. Davey, P. G. & Williams, A. H. (1991). A review of the safety profile of teicoplanin. Journal of Antimicrobial Chemotherapy 27, Suppl. B. 69-73.
8. de Lalla, F., Nicolin, R., Rinaldi, E., Scarpellini, P., Rigoli, R., Manfrin, V. et al. (1992). Prospective study of oral teicoplanin versus oral vancomycin for therapy of pseudomembranous colitis and Clostridium difficile-associated diarrhea. Antimicrobial Agents and Chemotherapy 36, 2192-6.
9. Farber, J. & Moellering, R. C. (1983). Retrospective study of preparations of vancomycin from 1974 to 1981. Antimicrobial Agents and Chemotherapy 23, 138-41.
10. Gerard, M., van der Auwera, P., Meunier, F., Ninove, D., Danneau, D. & Klasterski, J. (1987). A controlled clinical trial on efficacy and safety of teicoplanin (T) versus vancomycin (V) in the treatment of staphylococcal infections. In Program and Abstracts of the Twenty-Seventh Interscience Conference on Antimicrobial Agents and Chemotherapy 1987. Abstract 1039 p. 278. American Society for Microbiology, Washington, DC.
11. Gilbert, D. N., Wood C. A. & Kimbrough, R. C. (1991). Failure of treatment with teicoplanin at 6 milligrams/kilogram,1 day in patients with Staphylococcus aureus intravascular infection. Antimicrobial Agents and Chemotherapy 35, 79-87.
12. Hedström S. A. (1994). Teicoplanin vs. vancomycin in severe Gram-positive infection - a multicentre Scandinavian trial. In Abstracts of the Seventh European Congress of Clinical Microbiology and Infectious Diseases, Vienna, Austria, 1995. Abstract 760, p. 232.
13. Kaatz, G. W., Seo, S. M., Dorman, N. J. & Lerner, S. A. (1990). Emergence of teicoplanin resistance during therapy of Staphylococcus aureus endocarditis. Journal of Infectious Diseases 162, 103-8.
14. Kucers, A. (1984). Vancomycin. Journal of Antimicrobial Chemotherapy 14, 564-66.
15. Kulmala, H. K., Heilman, C. J., Kuzma, R. J., Sullivan, W. A., Stephens, G. J. & Rios, I. (1990). A randomised, blinded, comparative study of teicoplanin versus vancomycin in the treatment of vascular-access-associated bacteremia/septicemia caused by Gram-positive bacteria (Protocol 102-009). Data on file, Marion Merrell Dow.
16. Kureshi, A., Jewesson, P. J., Rubinger, M., Cole, C. D., Reece, D. E., Phillips, G. L., et al. (1991). Double-blind comparison of teicoplanin versus vancomycin in febrile neutropenic patients receiving concomitant tobramycin and piperacillin: effect on cyclosporin A-associated nephrotoxicity. Antimicrobial Agents and Chemotherapy 35, 2246-52.
17. Mellor, J. A., Kingdom, J., Cafferkey, M. & Keane, C. T. (1985). Vancomycin toxicity: a prospective study. Journal of Antimicrobial Chemotherapy 15, 773-80.
18. Menichetti, F., Martino, P., Bucaneve, G., Gentile, G., Dantonio, D., Liso, V. et al. (1994). Effects of teicoplanin and those of vancomycin in initial empirical antibiotic regimen in febrile, neutropenic patients with haematological malignancies. Antimicrobial Agents and Chemotherapy 38, 2041-6.
19. Neville, L. O., Brumfitt, W., Hamilton-Miller, J. M. T. & Harding, I. (1995). Teicoplanin vs. vancomycin for the treatment of serious infections: a randomised trial. International Journal of Antimicrobial Agents 5, 187-93.
20. Reynolds, P. E. & Somner, E. A. (1990). Comparison of the target sites and mechanisms of action of glycopeptide and lipoglycopeptide antibiotics. Drugs under Experimental and Clinical Research 16, 385-9.
21. Sage, R., Hann, I., Prentice, H. G., Devereux, S., Corringham, R., Hoffbrand, A. V. et al. (1988). A randomised trial of empirical antibiotic therapy with one of four beta-lactam antibiotics in combination with netilmicin in febrile neutropenic patients. Journal of Antimicrobial Chemotherapy 22, 237-47.
22. Sanyal, D., Johnson, A. P., George, R. C., Cookson, B. D. & Williams, A. J. (1991). Peritonitis due to vancomycin-resistant Staphylococcus epidermidis. Lancet 337, 54.
23. Smith, S. R., Cheesbrough, J., Spearing, R. & Davies, J. M. (1989). Randomised prospective study comparing vancomycin with teicoplanin in the treatment of infections associated with Hickman catheters. Antimicrobial Agents and Chemotherapy 33, 1193-7.
24. Thompson, G. A., Smithers, J. A., Kenny, M. T. . Dulworth, J. K., Kulmala, H. K., Yuh, L. et al. (1992). Pharmacokinetics of teicoplanin upon multiple dose administration to normal healthy male volunteers. Biopharmaceuticals and Drug Disposition 13, 213-20.
25. Van der Auwera, P., Aoun, M. & Meunier, F. (1991). Randomized study of vancomycin versus teicoplanin for the treatment of gram-positive bacterial infections in immunocompromised patients. Antimicrobial Agents and Chemotherapy 35, 451-7.
26. Van Laethem, Y., Hermans, P., De Wit, S., Goosens, H. & Clumeck, N. (1988). Teicoplanin compared with vancomycin in methicillin-resistant Staphylococcus aureus infections: preliminary results. Journal of Antimicrobial Chemotherapy 21, Suppl. A, 81-7.
27. Wilson, A. P. R., Grüneberg, R. N. & Neu, H. (1994). A critical review of the dosage of teicoplanin in Europe and the USA. International Journal of Antimicrobial Agents 4, Suppl. 1, S1-30.